EGFR-targeted therapies have been explored, with blocking of EGFR resulting in inhibition of cell proliferation, enhancement of apoptosis, and reduction in the metastatic and angiogenic potential of HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.